Otsuka Pharmaceutical Development & Commercialization

79 total trials 35 currently recruiting 40 completed

Trial Pipeline

RECRUITING Phase 1

A Trial to Assess How Centanafadine Interacts With Stimulants in the Body

NCT07314333

RECRUITING Phase 3

A Study to Evaluate the Safety and Efficacy of JNT-517 in Participants With Phenylketonuria (PKU)

NCT06971731

RECRUITING Phase 2

A Phase 2 Study of JNT-517 in Adolescent Participants With Phenylketonuria

NCT06637514

RECRUITING Phase 3

P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety

NCT06973577

RECRUITING Phase 3

A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia

NCT06894212

RECRUITING Phase 2

Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue

NCT06740526

RECRUITING Phase 3

A Study to See Iftolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old withAutosomal Recessive Polycystic Kidney Disease (ARPKD)

NCT04782258

ACTIVE NOT RECRUITING Phase 2

A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's

NCT06928142

ACTIVE NOT RECRUITING Phase 1

First-in-Human, Multiple Part Clinical Study of JNT-517 in Healthy Participants and in Participants With Phenylketonuria

NCT05781399

ACTIVE NOT RECRUITING Phase 3

Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)

NCT05248646

ACTIVE NOT RECRUITING Phase 3

A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder.

NCT05279313

COMPLETED Phase 1

A Trial to Test the Effects of Other Drugs on SEP-380135 in Healthy Men and Women

NCT07305779

COMPLETED Phase 1

A Clinical Study to Learn if SEP-363856 Has Physical Dependence in Adults With Schizophrenia

NCT05848700

COMPLETED Phase 1

Trial to Demonstrate the Equivalence of Two Different Strengths of Oral Centanafadine Capsules in Healthy Subjects

NCT07486895

COMPLETED Phase 1

A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard

NCT05402111

COMPLETED Phase 1

A Clinical Trial Study to Determine the Effect of an Investigational Drug (SEP-363856) Has on the Way That the Drug Metformin Travels Through the Body in People With Schizophrenia.

NCT04865835

COMPLETED Phase 2

Evaluating the Safety and Tolerability of Brexpiprazole in the Treatment of Adults With Borderline Personality Disorder (BPD)

NCT04186403

COMPLETED Phase 3

A 12-week Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type

NCT03594123

COMPLETED Phase 3

A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder

NCT03538691

COMPLETED Phase 3

A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes, Associated With Bipolar I Disorder

NCT03257865

COMPLETED Phase 3

A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes Associated With Bipolar I Disorder

NCT03259555

COMPLETED Phase 1

Study to Determine the Pharmacokinetics, Safety & Tolerability of Aripiprazole in Adults With Schizophrenia

NCT03150771

COMPLETED Phase 1

Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia

NCT02411695

COMPLETED Phase 3

Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress

NCT02196506

COMPLETED

Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo

NCT02192554

COMPLETED Phase 3

Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type

NCT01922258

COMPLETED Phase 3

A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation

NCT01862640

COMPLETED Phase 1

A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis

NCT01702181

COMPLETED Phase 3

Efficacy Study of OPC-34712 in Adults With Acute Schizophrenia

NCT01393613

COMPLETED Phase 3

Study of the Effectiveness of Three Different Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia

NCT01396421

COMPLETED Phase 1

Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects With Schizophrenia or Schizoaffective Disorder

NCT01423916

COMPLETED

Observational Study in Patients With Autosomal Dominant Polycystic Kidney Disease

NCT01430494

COMPLETED Phase 2

Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD

NCT01210560

COMPLETED Phase 2

IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients

NCT01009840

COMPLETED Phase 2

Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder

NCT01074294

COMPLETED Phase 2

Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder

NCT01052077

COMPLETED Phase 2

PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients

NCT00948090

COMPLETED Phase 2

Multicenter, Open-label, Safety and Tolerability Study

NCT01649557

COMPLETED Phase 3

Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia

NCT00731549

COMPLETED Phase 3

Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia

NCT00705783

COMPLETED Phase 1

Aripiprazole and Effexor XR Drug Interaction Study

NCT00362271

COMPLETED Phase 1

Drug-drug Interaction Study of Aripiprazole and Lamotrigine in Patients With Bipolar Type I Disorder

NCT00321516

COMPLETED Phase 4

A Phase IV Study of the Safety and Efficacy of Aripiprazole in Combination With Lamotrigine in the Long-Term Maintenance Treatment of Patients With Bipolar I Disorder With A Recent Manic or Mixed Episode

NCT00277212

COMPLETED Phase 4

A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania

NCT00261443

COMPLETED Phase 3

A Study of Aripiprazole in Patients With Major Depressive Disorder

NCT00105196

COMPLETED Phase 2

Heart Pressure Assessment Study With Tolvaptan to Treat Congestive Heart Failure

NCT00132886

COMPLETED Phase 3

A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode

NCT00094432

COMPLETED Phase 3

Aripiprazole Oral Acceptability Trial

NCT00101569

COMPLETED Phase 3

Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed With Dementia

NCT00095719

COMPLETED Phase 4

Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease

NCT00095810

COMPLETED Phase 3

Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type

NCT00041678

Phase Distribution

PhaseTrial count
Phase 1 13
Phase 2 11
Phase 3 50
Phase 4 3

What the Pipeline for Otsuka Pharmaceutical Development & Commercialization Shows

According to the ClinicalTrials.gov registry, Otsuka Pharmaceutical Development & Commercialization is linked to 79 US clinical trials across every stage of research activity. Of those, 35 studies are currently recruiting — about 44% of the sponsor's indexed portfolio — and 40 are already marked complete, representing roughly 51% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.

The phase mix for Otsuka Pharmaceutical Development & Commercialization reports 53 late-stage studies (Phase 3 and Phase 4 combined) and 24 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.

The top therapeutic focus area indexed for Otsuka Pharmaceutical Development & Commercialization is Schizophrenia with 12 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial